892550-41-3

Basic information

• Product Name: (+/-)-2-[9-chloro-6-(3,4-dihydroxy-3-methylbut-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]isophthalonitrile
• Synonyms: (+/-)-2-[9-chloro-6-(3,4-dihydroxy-3-methylbut-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]isophthalonitrile
• CAS NO: 892550-41-3
• Molecular Weight: 476.922
• Mol File: 892550-41-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (+/-)-2-[9-chloro-6-(3,4-dihydroxy-3-methylbut-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]isophthalonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: (+/-)-2-[9-chloro-6-(3,4-dihydroxy-3-methylbut-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]isophthalonitrile(892550-41-3)
• EPA Substance Registry System: (+/-)-2-[9-chloro-6-(3,4-dihydroxy-3-methylbut-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]isophthalonitrile(892550-41-3)

Safety Data

• Hazardous Substances Data: 892550-41-3(Hazardous Substances Data)

Upstream product

• 122-01-0 4-chloro-benzoyl chloride 
• 57082-98-1 (E)-1-bromo-4-(4-chlorostyryl)benzene 
• 7461-38-3 4-chloro-N,N-diethyl-benzamide 
• 5551-11-1 4-Chloro-2-nitrobenzaldehyde 
• 937053-63-9 6-chloro-phenanthren-9-ol 
• 892550-47-9 (2E)-2-(4-bromophenyl)-3-(4-chloro-2-nitrophenyl)acrylic acid 
• 892550-48-0 (2E)-3-(2-amino-4-chlorophenyl)-2-(4-bromophenyl)acrylic acid 
• 1193719-23-1 6-bromo-3-chlorophenanthrene-9-carboxylic acid 
• 938070-94-1 9-bromo-6-chloro-2-(2,6-dibromophenyl)-1H-phenanthro[9,10-d]imidazole acetic acid salt 
• 892549-58-5 2-[9-chloro-6-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]isophthalonitrile 
• 892549-54-1 2-[9-chloro-6-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]isophthalonitrile 
• 892550-46-8 9-bromo-6-chloro-2-(2,6-dibromophenyl)-1H-phenanthro[9,10-d]imidazole 
• 892550-54-8 2-[6-chloro-9-(3-methylbut-3-en-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]isophthalonitrile 
• 75-65-0 tert-butyl alcohol 

Relevant articles and documents

METHODS FOR TREATING OR PREVENTING NEOPLASIAS

The present invention is directed to a method for treating or preventing a neoplasia in a human patient in need of such treatment comprising administering to the patient a compound that inhibits microsomal prostaglandin E synthase-1 in an amount that is effective for treating or preventing the neoplasia.